New More Polar Symmetrical Bipyridinic Compounds: New Strategy for the Inhibition of Choline Kinase α1

References

• Kennedy EP . Metabolism of lipids. Ann. Rev. Biochem.26, 119–148 (1957).
   PubMed Web of Science ®Google Scholar
• Wu G , AoyamaC, YoungSG, VanceDE. Early embryonic lethality caused by disruption of the gene for choline kinase alpha, the first enzyme in phosphatidylcholine biosynthesis. J. Biol. Chem.283, 1456–1462 (2008).
   PubMed Web of Science ®Google Scholar
• Aoyama C , LiaoH, IshidateK. Structure and function of choline kinase isoforms in mammalian cells. Progress in lipid research.43, 266–281 (2004).
   PubMed Web of Science ®Google Scholar
• Aoyama C , OhtaniA, IshidateK. Expression and characterization of the active molecular forms of choline/ethanolamine kinase-alpha and -beta in mouse tissues, including carbon tetrachloride-induced liver. Biochem. J.363, 777–784 (2002).
   PubMed Web of Science ®Google Scholar
• Gallego-Ortega D , Ramirez de MolinaA, RamosMAet al. Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PloS ONE4, e7819 (2009).
   PubMed Web of Science ®Google Scholar
• Ramirez de Molina A , GutierrezR, RamosM Aet al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene21, 4317–4322 (2002).
   PubMed Web of Science ®Google Scholar
• Ramirez de Molina A , Rodriguez-GonzalezA, GutierrezRet al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem. Biophys. Res. Commun.296, 580–583 (2002).
   PubMed Web of Science ®Google Scholar
• Ramirez de Molina A , Sarmentero-EstradaJ, Belda-IniestaCet al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol.8, 889–897 (2007).
   PubMed Web of Science ®Google Scholar
• Nakagami K , UchidaT, OhwadaSet al. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn. J. Cancer Res.90, 419–424 (1999).
   PubMedGoogle Scholar
• Iorio E , MezzanzanicaD, AlbertiPet al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res.65, 9369–9376 (2005).
   PubMed Web of Science ®Google Scholar
• Iorio E , RicciA, BagnoliMet al. Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res.70, 2126–2135 (2010).
   PubMed Web of Science ®Google Scholar
• Hernando E , Sarmentero-EstradaJ, KoppieTet al. A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas. Oncogene28, 2425–2435 (2009).
   PubMed Web of Science ®Google Scholar
• Gallego-Ortega D , Ramirez De MolinaA, GutierrezRet al. Generation and characterization of monoclonal antibodies against choline kinase alpha and their potential use as diagnostic tools in cancer. Int. J. Oncol.29, 335–340 (2006).
   PubMed Web of Science ®Google Scholar
• Clem BF , ClemAL, YalcinAet al. A novel small molecule antagonist of choline kinase-alpha that simultaneously suppresses MAPK and PI3K/AKT signaling. Oncogene30, 3370–3380 (2011).
   PubMed Web of Science ®Google Scholar
• Ramírez de Molina A , Sarmentero-EstradaJ, Belda-IniestaCet al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol.8, 889–897 (2007).
   PubMed Web of Science ®Google Scholar
• Granata A , NicolettiR, TinagliaVet al. Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. Br. J. Cancer110, 330–340 (2014).
   PubMed Web of Science ®Google Scholar
• Glunde K , RamanV, MoriNet al. RNA Interference–mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res.65, 11034–11043 (2005).
   PubMed Web of Science ®Google Scholar
• Gruber J , See TooWCet al. Balance of human choline kinase isoforms is critical for cell cycle regulation: implications for the development of choline kinase-targeted cancer therapy. FEBS J.279, 1915–1928 (2012).
   PubMed Web of Science ®Google Scholar
• Hernandez-Alcoceba R , FernandezF, LacalJC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res.59, 3112–3118 (1999).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gonzalez A , Ramirez de MolinaA, FernandezFet al. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene22, 8803–8812 (2003).
   PubMed Web of Science ®Google Scholar
• Clem BF , ClemAL, YalcinAet al. A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling. Oncogene30, 3370–3380 (2011).
   PubMed Web of Science ®Google Scholar
• Krishnamachary B , GlundeK, WildesFet al. Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res.69, 3464–3471 (2009).
   PubMed Web of Science ®Google Scholar
• Ramírez de Molina A , Rodríguez-GonzálezA, LacalJC. From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design. Cancer Lett.206, 137–148 (2004).
   PubMed Web of Science ®Google Scholar
• Hernández-Alcoceba R , SanigerL, CamposJet al. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene15, 2289–2301 (1997).
   PubMed Web of Science ®Google Scholar
• Teegarden D , TaparowskyEJ, KentC. Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with the Harvey-ras OncogeneJ. Biol. Chem.265, 6042–6047 (1990).
   PubMed Web of Science ®Google Scholar
• Campos JM , NunezMC, Sánchez-Martin, RMet al. Quantitative structure–activity relationships for a series of symmetrical bisquaternary anticancer compounds. Bioorg. Med. Chem.10, 2215–2231 (2002).
   PubMed Web of Science ®Google Scholar
• Campos JM , NunezMC, RodriguezVet al. QSAR of 1,1′-(1,2-ethylenebisbenzyl)bis(4-substitutedpyridinium) dibromides as choline kinase inhibitors: a different approach for antiproliferative drug design. Bioorg. Med. Chem. Lett.10, 767–770 (2000).
   PubMed Web of Science ®Google Scholar
• Campos JM , NunezMC, RodriguezVet al. LUMO energy of model compounds of bispyridinium compounds as an index for the inhibition of choline kinase. Eur. J. Med. Chem.36, 215–225 (2001).
   PubMed Web of Science ®Google Scholar
• Conejo-García A , Bañez-CoronelM, Sánchez-MartínR. Met al. Influence of the linker in bispyridium compounds on the inhibition of human choline kinase. J. Med. Chem.47, 5433–5440 (2004).
   PubMed Web of Science ®Google Scholar
• Sánchez-Martín RM , CamposJM, Conejo-GarcíaAet al. Symmetrical bis-quinolinium compounds: new human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line. J. Med. Chem.48, 3354–3363 (2005).
   PubMed Web of Science ®Google Scholar
• Gómez-Pérez V , McSorleyT, See TooWCet al. Novel 4-amino bis-pyridinium and bis-quinolinium derivatives as choline kinase inhibitors with antiproliferative activity against the human breast cancer SKBR-3 cell line. Chem. Med. Chem.7, 663–669 (2012).
   Google Scholar
• Al-Saffar NM , TroyH, Ramírez de MolinaAet al. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res.66, 427–434 (2006).
   PubMed Web of Science ®Google Scholar
• Mori N , GlundeK, TakagiTet al. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res.67, 11284–11290 (2007).
   PubMed Web of Science ®Google Scholar
• Banez-Coronel M , Ramírez de MolinaA, Rodríguez-GonzálezAet al. Choline kinase alpha depletion selectively kills tumoral cells. Curr. Cancer Drug Targets8, 709–719 (2008).
   PubMed Web of Science ®Google Scholar
• Hernández-Alcoceba R , FernándezF, LacalJC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res.59, 3112–3118 (1999).
   PubMed Web of Science ®Google Scholar
• Rodríguez-González A , Ramírez de MolinaA, FernándezFet al. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene23, 8247–8259 (2004).
   PubMed Web of Science ®Google Scholar
• Lloveras J , HamzaM, ChapHet al. Action of hemicholinium-3 on phospholipid metabolism in Krebs II ascites cells. Biochem. Pharmacol.34, 3987–3993 (1985).
   PubMed Web of Science ®Google Scholar
• Cannon JG . Structure-activity aspects of hemicholinium-3 (HC-3) and its analogs and congeners. Med. Res. Rev.14, 505–531 (1994).
   PubMed Web of Science ®Google Scholar
• Ramirez de Molina A , Banez-CoronelM, GutierrezRet al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res.64, 6732–6739 (2004).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Gónzalez A , Ramírez de MolinaA, Banez-CoronelMet al. Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. Int. J. Oncol.26, 999–1008 (2005).
   PubMed Web of Science ®Google Scholar
• Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors. http://clinicaltrials.gov/ct2/show/NCT01215864
   Google Scholar
• Milanese L , EspinosaA, CamposJMet al. Insight into the inhibition of human choline kinase: homology modeling and molecular dynamics simulations. ChemMedChem1, 1216–1228 (2006).
   PubMed Web of Science ®Google Scholar
• Hong BS , Allali-HassaniA, TempelWet al. Crystal structures of human choline kinase isoforms in complex with hemicholinium-3: single amino acid near the active site influences inhibitor sensitivity. J. Biol. Chem.285, 16330–16340 (2010).
   PubMed Web of Science ®Google Scholar
• Srivani P , SastryGN. Potential choline kinase inhibitors: a molecular modeling study. J. Mol. Graph. Model.27, 676–688 (2009).
   PubMed Web of Science ®Google Scholar
• Sanchez-Lopez E , ZimmermanT, Gomez del PulgarTet al. Choline kinase inhibition induces exacerbated endoplasmic reticulum stress and triggers apoptosis via CHOP in cancer cells. Cell Death Dis.4, e933 (2013).
   PubMed Web of Science ®Google Scholar
• Rubio-Ruiz B , Conejo-GarcíaA, Ríos-MarcoPet al. Design, synthesis, theoretical calculations and biological evaluation of new non symmetrical choline kinase inhibitors. Eur. J. Med. Chem.50, 154–162 (2012).
   PubMed Web of Science ®Google Scholar
• Schiaffino-Ortega S , López-CaraLC, Ríos-MarcoPet al. New non-symmetrical choline kinase inhibitors. Bioorg. Med. Chem.21, 7146–7154 (2013).
   PubMed Web of Science ®Google Scholar
• Sahún-Roncero M , Rubio-RuizB, SaladinoGet al. The mechanism of allosteric coupling in choline kinase α1 revealed by the action of a rationally designed inhibitor. Angew. Chem. Int. Ed. Engl.52, 4582–4586 (2013).
   PubMed Web of Science ®Google Scholar
• Sahún-Roncero M , Rubio-RuízB, Conejo-GarcíaAet al. Determination of potential scaffolds for human choline kinase α1 by chemical deconvolution studies. ChemBioChem14, 1291–1295 (2013).
   PubMed Web of Science ®Google Scholar
• Rubio Ruiz B , Ramos-TorrecillasJ, Capitán-CañadasMet al. Antiproliferative activity, cell cycle, and apoptosis studies of a series of 6-substituted 9H-Purin-9-yl-pyridinium derivatives on a human cervical carcinoma cell line. ChemMedChem8, 1266–1269 (2013).
   PubMed Web of Science ®Google Scholar
• Rubio-Ruiz B , Figuerola-ConchasA, Ramos-TorrecillasJet al. Discovery of a new binding site on human choline kinase α1: design, synthesis, crystallographic studies, and biological evaluation of asymmetrical bispyridinium derivative. J. Med. Chem.57, 507–515 (2014).
   PubMed Web of Science ®Google Scholar
• Patani GA , LaVoieEJ. Bioisosteris. A rational approach in drug design. Chem. Rev.96, 3147–3176 (1996).
   PubMed Web of Science ®Google Scholar
• Olesen PH . The use of bioisosteric groups in lead optimization. Curr. Opin. Drug Discov. Dev.4, 471–478 (2001).
   PubMedGoogle Scholar
• Everitt S , KnegtelR, MortimoreM, Rutherford, A. PCT Int. Appl. WO 2013/043960 A1.
   Google Scholar
• Keshtov ML , VasnevVA, MarkovaGDet al. New conjugated polyfluorenes carrying main-chain bipyridyl fragments as efficient fluorescent chemosensors for transition-metal ions. Polymer Sci. Ser. B53, 345–351 (2011).
   Web of Science ®Google Scholar
• Wang Q , WangL, YuL. Synthesis and unusual physical behavior of a photorefractive polymer containing tris(bipyridyl)ruthenium(II) complexes as a photosensitizer and exhibiting a low glass-transition temperature. J. Am. Chem. Soc.120, 12860–12868 (1998).
   Web of Science ®Google Scholar
• Dumur F , MayerCR, DumasEet al. New chelating stilbazonium-like dyes from Michler's ketone. Organ. Lett.10, 321–324 (2008).
   PubMed Web of Science ®Google Scholar
• Vermes I , HaanenC, Steffens-NakkenHet al. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods184, 39–51 (1995).
   PubMed Web of Science ®Google Scholar
• Ly JD , GrubbDR, LawenA. The mitochondrial membrane potential (Δψm) in apoptosis: an update. Apoptosis3, 115–128 (2003).
   Google Scholar
• Green DR , KroemerG. The pathophysiology of mitochondrial cell death. Science305, 626–629 (2005).
   Web of Science ®Google Scholar
• Salvioli S , ArdizzoniA, FranceschiC, CossarizzaA. JC-1 but not DiOC6(3) or rhodamine 123 is a reliable fluorescent probe to asses ΔΨ changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett.411, 77–82 (1997).
   PubMed Web of Science ®Google Scholar
• Soldani C , ScovassiA. I. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis7, 321–328 (2002).
   PubMed Web of Science ®Google Scholar
• SYBYL-X 2.0, Tripos International, 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA. www.tripos.com
   Google Scholar
• Conejo-García A , CamposJM, EntrenaAet al. Conformational dynamics of a bispyridinium cyclophane. J. Org. Chem.68, 8697–869 (2003).
   PubMed Web of Science ®Google Scholar
• Gaussian Inc, Wallingford CT , www.gaussian.com
   Google Scholar
• Jain AN . Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J. Comput. Aided Mol. Des.21, 281–306 (2007).
   PubMed Web of Science ®Google Scholar
• The PyMOL Molecular Graphics System, Version 1.4, Schrödinger, LLC.
   Google Scholar
• Romagnoli R , BaraldiPG, Lopez-CaraCet al. Concise synthesis and biological evaluation of 2-aroyl-5-amino benzo[b]thiophene derivatives as a novel class of potent antimitotic agents. J. Med. Chem.56, 9296–9309 (2013).
   PubMedGoogle Scholar
• Porcù E , ViolaG, BortolozziRet al. TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis. Angiogenesis16, 647–662 (2013).
   PubMed Web of Science ®Google Scholar